FDA Launches Safety Review of TNF Inhibitors in Children
The U.S. Food and Drug Administration released an early communication regarding a plan to investigate a possible association between TNF inhibitor therapy and cancer in children receiving these agents for treatment of juvenile idiopathic arthritis (JIA) and Crohn’s disease.
Prednisone, but not TNF inhibitors, is associated with an increased risk of serious infection in older RA patients
Older person with rheumatoid arthritis (RA) make up an increasing proportion of those treated with biologic disease modifying anti-rheumatic agents (DMARDs). The safety of these agents may differ for this subgroup of older RA patients, yet effects have generally not been selectively studied in this population.